BCLI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BCLI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of Dec23, Brainstorm Cell Therapeutics's earnings power value is $-0.07. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is N/A
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
The historical data trend for Brainstorm Cell Therapeutics's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brainstorm Cell Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Earnings Power Value (EPV) | Get a 7-Day Free Trial | - | 1.08 | 0.48 | - | 0.02 |
Brainstorm Cell Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Earnings Power Value (EPV) | Get a 7-Day Free Trial | - | -0.02 | -0.03 | -0.01 | 0.02 |
For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Brainstorm Cell Therapeutics's Earnings Power Value (EPV) falls into.
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
Brainstorm Cell Therapeutics's "Earning Power" Calculation:
Average of Last 20 Quarters | Last Quarter | |
Revenue | 0.00 | |
DDA | 0.24 | |
Operating Margin % | 0.00 | |
SGA * 25% | 2.30 | |
Tax Rate % | 0.00 | |
Maintenance Capex | 0.32 | |
Cash and Cash Equivalents | 1.30 | |
Short-Term Debt | 0.60 | |
Long-Term Debt | 0.67 | |
Shares Outstanding (Diluted) | 51.54 |
1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.
2. Look at average margins over a business/Industry cycle: Average Operating Margin = 0.00%
To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.
3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:
To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = $0.00 Mil, Average Operating Margin = 0.00%, Average Adjusted SGA = 2.30,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 0.00 * 0.00% +2.30 = $ Mil.
4. Multiply by one minus Average Tax Rate (NOPAT):
Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = 0.00%, and "Normalized" EBIT = $ Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = * ( 1 - 0.00% ) = $0 Mil.
5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:
Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 0.24 * 0.5 * 0.00% = $0 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = 0 + 0 = $0 Mil.
6. Adjusted for Maintenance Capital Expenditure:
First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
Brainstorm Cell Therapeutics's Average Maintenance CAPEX = $0.32 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%
8. Brainstorm Cell Therapeutics's current cash and cash equivalent = $1.30 Mil.
Brainstorm Cell Therapeutics's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 0.67 + 0.60 = $1.275 Mil.
Brainstorm Cell Therapeutics's current Shares Outstanding (Diluted Average) = 51.54 Mil.
Brainstorm Cell Therapeutics's Earnings Power Value (EPV) for Dec23 is calculated as:
EPV | = | ( ( Norm. Earnings | - | Maint. CAPEX *) | / | WACC | + | CashandEquiv | - | Int. Bearing Debt ) | / | Shares Outstanding (Diluted Average) |
= | ( ( 0 | - | 0.32) | / | 9% | + | 1.30 | - | 1.275 ) | / | 51.54 | |
= | -0.07 |
Margin of Safety (EPV) | = | ( Earnings Power Value (EPV) | - | Current Price ) | / | Earnings Power Value (EPV) |
= | ( -0.069087365495771 | - | 0.5396 ) | / | -0.069087365495771 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Brainstorm Cell Therapeutics (NAS:BCLI) Earnings Power Value (EPV) Explanation
Assumption: Current profitability is sustainable.
Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.
Be Aware
Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.
Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Earnings Power Value (EPV) provided by GuruFocus.com. Please click on the following links to see related term pages.
Stacy Lindborg | officer: EVP, Head Global Clin Research | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019 |
Nir Naor | director | BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019 |
Kirk Taylor | officer: Chief Medical Officer | C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019 |
Menghisteab Bairu | director | C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019 |
Alla Patlis | officer: See Remarks | C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601 |
Anthony Waclawski | officer: See Remarks | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019 |
Chaim Lebovits | officer: Chief Executive Officer | 110 EAST 59TH STREET, NEW YORK NY 10019 |
David Setboun | officer: EVP and COO | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019 |
Acc International Holdings Ltd. | other: Member of 10% owner group | MORGAN & MORGAN BUILDING, PASEA ESTATE, ROAD TOWN, TORTOLA D8 VG 1110 |
Sankesh Abbhi | director | 3119 PONCE DE LEON, UNIT C, CORAL GABLES FL 33134 |
Jacob A Frenkel | director | 188 E. 70TH ST., #29A, NEW YORK NY 10021 |
Arturo Araya | officer: Chief Commercial Officer | C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601 |
Preetam Shah | officer: EVP, CFO and Treasurer | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019 |
Ralph Dr. Kern | officer: COO and Chief Medical Officer | C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601 |
Irit Arbel | director | 6 HADISHON STREEET, JERUSALEM, ISRAEL 96596 L3 00000 |
From GuruFocus
By PRNewswire • 12-10-2023
By PRNewswire • 12-20-2023
By PRNewswire • 12-06-2023
By PRNewswire • 11-30-2023
By PRNewswire • 11-28-2023
By PRNewswire • 12-12-2023
By PRNewswire • 01-02-2024
By PRNewswire • 12-29-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.